Anti-ferroptotic mechanism of IL4i1-mediated amino acid metabolism

  1. Leonie Zeitler
  2. Alessandra Fiore
  3. Claudia Meyer
  4. Marion Russier
  5. Gaia Zanella
  6. Sabine Suppmann
  7. Marco Gagaro
  8. Sachdev S Sidhu
  9. Somasekar Seshagiri
  10. Caspar Ohnmacht
  11. Thomas Köcher
  12. Francesca Fallarino
  13. Andreas Linkermann
  14. Peter J Murray  Is a corresponding author
  1. Max Planck Institute for Biochemistry, Germany
  2. Universitätsklinikum Carl Gustav Carus Dresden, Germany
  3. Max Planck Institute of Biochemistry, Germany
  4. Università degli Studi di Perugia, Italy
  5. University of Toronto, Canada
  6. SciGenom, India
  7. Helmholtz Zentrum, Germany
  8. Vienna BioCenter, Austria
  9. Technical University of Dresden, Germany

Abstract

Interleukin-4-induced-1 (IL4i1) is an amino acid oxidase secreted from immune cells. Recent observations have suggested that IL4i1 is pro-tumorigenic via unknown mechanisms. As IL4i1 has homologues in snake venoms (LAAO, L-amino acid oxidases), we used comparative approaches to gain insight into the mechanistic basis of how conserved amino acid oxidases regulate cell fate and function. Using mammalian expressed recombinant proteins, we found venom LAAO kills cells via hydrogen peroxide generation. By contrast, mammalian IL4i1 is non-cytotoxic and instead elicits a cell productive gene expression program inhibiting ferroptotic redox death by generating indole-3-pyruvate (I3P) from tryptophan. I3P suppresses ferroptosis by direct free radical scavenging and through the activation of an anti-oxidative gene expression program. Thus, the pro-tumor effects of IL4i1 are likely mediated by local anti-ferroptotic pathways via aromatic amino acid metabolism, arguing that an IL4i1 inhibitor may modulate tumor cell death pathways.

Data availability

RNAseq data have been deposited in GEO under accession code GSE161159, GSE167136.

Article and author information

Author details

  1. Leonie Zeitler

    Immunoregulation, Max Planck Institute for Biochemistry, Martinsried, Germany
    Competing interests
    No competing interests declared.
  2. Alessandra Fiore

    Immunoregulation, Max Planck Institute for Biochemistry, Martinsried, Germany
    Competing interests
    No competing interests declared.
  3. Claudia Meyer

    Sektion Nephrologie, Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany
    Competing interests
    No competing interests declared.
  4. Marion Russier

    Immunoregulation, Max Planck Institute of Biochemistry, Martinsried, Germany
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9633-9804
  5. Gaia Zanella

    Immunoregulation, Max Planck Institute for Biochemistry, Martinsried, Germany
    Competing interests
    No competing interests declared.
  6. Sabine Suppmann

    Immunoregulation, Max Planck Institute for Biochemistry, Martinsried, Germany
    Competing interests
    No competing interests declared.
  7. Marco Gagaro

    Dipartimento di medicina e chirurgia, Università degli Studi di Perugia, Perugia, Italy
    Competing interests
    No competing interests declared.
  8. Sachdev S Sidhu

    Donnelly Centre, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7755-5918
  9. Somasekar Seshagiri

    Research Foundation, SciGenom, Bangalore, India
    Competing interests
    No competing interests declared.
  10. Caspar Ohnmacht

    Center of Allergy and Environment, Helmholtz Zentrum, Munich, Germany
    Competing interests
    No competing interests declared.
  11. Thomas Köcher

    Core Facilities GmbH, Vienna BioCenter, Vienna, Austria
    Competing interests
    Thomas Köcher, Thomas Köcher is affiliated with Vienna BioCenter Core Facilities GmbH. The author has no financial interests to declare..
  12. Francesca Fallarino

    Dipartimento di medicina e chirurgia, Università degli Studi di Perugia, Perugia, Italy
    Competing interests
    No competing interests declared.
  13. Andreas Linkermann

    Technical University of Dresden, Dresden, Germany
    Competing interests
    No competing interests declared.
  14. Peter J Murray

    Immunoregulation, Max Planck Institute for Biochemistry, Martinsried, Germany
    For correspondence
    murray@biochem.mpg.de
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6329-9802

Funding

Deutsche Forschungsgemeinschaft (SFB-TRR 127)

  • Andreas Linkermann
  • Peter J Murray

Deutsche Forschungsgemeinschaft (FOR 2599)

  • Caspar Ohnmacht
  • Peter J Murray

Deutsche Forschungsgemeinschaft (SFB-TRR 205)

  • Andreas Linkermann

Max-Planck-Gesellschaft

  • Peter J Murray

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, Zeitler et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,441
    views
  • 772
    downloads
  • 75
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Leonie Zeitler
  2. Alessandra Fiore
  3. Claudia Meyer
  4. Marion Russier
  5. Gaia Zanella
  6. Sabine Suppmann
  7. Marco Gagaro
  8. Sachdev S Sidhu
  9. Somasekar Seshagiri
  10. Caspar Ohnmacht
  11. Thomas Köcher
  12. Francesca Fallarino
  13. Andreas Linkermann
  14. Peter J Murray
(2021)
Anti-ferroptotic mechanism of IL4i1-mediated amino acid metabolism
eLife 10:e64806.
https://doi.org/10.7554/eLife.64806

Share this article

https://doi.org/10.7554/eLife.64806

Further reading

    1. Cell Biology
    Xiaojiao Hua, Chen Zhao ... Yan Zhou
    Research Article

    The β-catenin-dependent canonical Wnt signaling is pivotal in organ development, tissue homeostasis, and cancer. Here, we identified an upstream enhancer of Ctnnb1 – the coding gene for β-catenin, named ieCtnnb1 (intestinal enhancer of Ctnnb1), which is crucial for intestinal homeostasis. ieCtnnb1 is predominantly active in the base of small intestinal crypts and throughout the epithelia of large intestine. Knockout of ieCtnnb1 led to a reduction in Ctnnb1 transcription, compromising the canonical Wnt signaling in intestinal crypts. Single-cell sequencing revealed that ieCtnnb1 knockout altered epithelial compositions and potentially compromised functions of small intestinal crypts. While deletion of ieCtnnb1 hampered epithelial turnovers in physiologic conditions, it prevented occurrence and progression of Wnt/β-catenin-driven colorectal cancers. Human ieCTNNB1 drove reporter gene expression in a pattern highly similar to mouse ieCtnnb1. ieCTNNB1 contains a single-nucleotide polymorphism associated with CTNNB1 expression levels in human gastrointestinal epithelia. The enhancer activity of ieCTNNB1 in colorectal cancer tissues was stronger than that in adjacent normal tissues. HNF4α and phosphorylated CREB1 were identified as key trans-factors binding to ieCTNNB1 and regulating CTNNB1 transcription. Together, these findings unveil an enhancer-dependent mechanism controlling the dosage of Wnt signaling and homeostasis in intestinal epithelia.

    1. Cell Biology
    2. Stem Cells and Regenerative Medicine
    Nathaniel Paul Meyer, Tania Singh ... Diane L Barber
    Research Article

    Our understanding of the transitions of human embryonic stem cells between distinct stages of pluripotency relies predominantly on regulation by transcriptional and epigenetic programs with limited insight on the role of established morphological changes. We report remodeling of the actin cytoskeleton of human embryonic stem cells (hESCs) as they transition from primed to naïve pluripotency which includes assembly of a ring of contractile actin filaments encapsulating colonies of naïve hESCs. Activity of the Arp2/3 complex is required for the actin ring, to establish uniform cell mechanics within naïve colonies, promote nuclear translocation of the Hippo pathway effectors YAP and TAZ, and effective transition to naïve pluripotency. RNA-sequencing analysis confirms that Arp2/3 complex activity regulates Hippo signaling in hESCs, and impaired naïve pluripotency with inhibited Arp2/3 complex activity is rescued by expressing a constitutively active, nuclear-localized YAP-S127A. Moreover, expression of YAP-S127A partially restores the actin filament fence with Arp2/3 complex inhibition, suggesting that actin filament remodeling is both upstream and downstream of YAP activity. These new findings on the cell biology of hESCs reveal a mechanism for cytoskeletal dynamics coordinating cell mechanics to regulate gene expression and facilitate transitions between pluripotency states.